{"transactions":[{"id":2297824,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2022-04-13T23:35:46.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":5000,"price":4.01,"value":20050.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c)."}],"balance_after":299941,"source":{"system":"sec-edgar","filing":"0001209191-22-024362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919122024362/doc4.xml","form_type":"4"}},{"id":2385694,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-18T23:56:26.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":115000,"derivative":{"exercise_price":11.02,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-22-011465","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919122011465/doc4.xml","form_type":"4"}},{"id":2551321,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-04T20:45:42.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":4718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":4718,"derivative":{"exercise_price":2.18,"exercise_date":"2021-09-30","expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":4718},"source":{"system":"sec-edgar","filing":"0001878894-21-000011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000187889421000011/edgar.xml","form_type":"4"}},{"id":2643711,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:06:47.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":3142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":3142,"derivative":{"exercise_price":3.27,"exercise_date":"2021-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":3142},"source":{"system":"sec-edgar","filing":"0001192482-21-000600","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248221000600/edgar.xml","form_type":"4"}},{"id":2648002,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T23:00:50.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":19763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2648001,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:50.000Z","date":"2021-04-18","kind":"exercise","acquired":false,"shares":3383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":159027,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":3383},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2648000,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:50.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":69604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":69604,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":69604},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647999,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:50.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":162410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":162410,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":162410},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647998,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T23:00:50.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":19763,"price":5.06,"value":100000.78,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":19763,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647997,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:50.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":91406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020,  and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":0,"derivative":{"exercise_price":0.3,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":91406},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647996,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:50.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":91406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020,  and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":91406,"derivative":{"exercise_price":0.3,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":91406},"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647995,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-01T23:00:50.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":8126,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":293471,"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647994,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-01T23:00:50.000Z","date":"2021-04-18","kind":"exercise","acquired":true,"shares":3383,"price":6.11,"value":20670.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":285345,"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2647993,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-01T23:00:50.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":91406,"price":0.3,"value":27421.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction occurred prior to the Issuer's initial public offering (\"IPO\") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":281962,"source":{"system":"sec-edgar","filing":"0000899243-21-027016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027016/doc4.xml","form_type":"4"}},{"id":2663002,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T20:41:07.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.56,"exercise_date":"2022-06-15","expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001192482-21-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248221000524/edgar.xml","form_type":"4"}},{"id":2760464,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-02T20:25:04.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":3783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":3783,"derivative":{"exercise_price":3.02,"exercise_date":"2021-03-31","expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":3783},"source":{"system":"sec-edgar","filing":"0001653224-21-000001","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000165322421000001/edgar.xml","form_type":"4"}},{"id":2919032,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-05T21:17:06.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":3877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":3877,"derivative":{"exercise_price":2.64,"exercise_date":"2020-12-31","expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":3877},"source":{"system":"sec-edgar","filing":"0001192482-21-000032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248221000032/edgar.xml","form_type":"4"}},{"id":3018167,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T20:43:41.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":4516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":4516,"derivative":{"exercise_price":2.275,"exercise_date":"2020-09-30","expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":4516},"source":{"system":"sec-edgar","filing":"0001192482-20-000759","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248220000759/edgar.xml","form_type":"4"}},{"id":3094881,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-01T21:49:23.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":3812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":3812,"derivative":{"exercise_price":2.6,"exercise_date":"2020-06-30","expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":3812},"source":{"system":"sec-edgar","filing":"0001192482-20-000595","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248220000595/edgar.xml","form_type":"4"}},{"id":3103992,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:11:07.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.51,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001192482-20-000544","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248220000544/edgar.xml","form_type":"4"}},{"id":3185796,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-02T20:49:37.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":4310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":4310,"derivative":{"exercise_price":2.48,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":4310},"source":{"system":"sec-edgar","filing":"0001578563-20-000008","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856320000008/primary_doc.xml","form_type":"4"}},{"id":3326649,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-02T21:56:53.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":2375,"derivative":{"exercise_price":5.39,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001578563-20-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856320000001/primary_doc.xml","form_type":"4"}},{"id":3398026,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-03T21:20:31.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.93,"expiration_date":"2029-08-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001578563-19-000030","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856319000030/primary_doc.xml","form_type":"4"}},{"id":3400415,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-02T20:30:19.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":3907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":3907,"derivative":{"exercise_price":3.29,"expiration_date":"2029-09-30","underlying":"Common Stock","underlying_shares":3907},"source":{"system":"sec-edgar","filing":"0001578563-19-000026","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856319000026/primary_doc.xml","form_type":"4"}},{"id":3470403,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T20:08:17.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2323,"derivative":{"exercise_price":5.44,"exercise_date":"2019-06-28","expiration_date":"2029-06-28","underlying":"Common Stock","underlying_shares":2323},"source":{"system":"sec-edgar","filing":"0001104659-19-039024","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465919039024/a4.xml","form_type":"4"}},{"id":3571504,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-01T19:39:12.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":1916,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1916,"derivative":{"exercise_price":5.84,"exercise_date":"2019-03-29","expiration_date":"2029-03-29","underlying":"Common Stock","underlying_shares":1916},"source":{"system":"sec-edgar","filing":"0001562180-19-002071","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218019002071/primarydocument.xml","form_type":"4"}},{"id":3712644,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-02T21:29:36.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":3439,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3439,"derivative":{"exercise_price":3.23,"exercise_date":"2018-12-31","expiration_date":"2028-12-30","underlying":"Common Stock","underlying_shares":3439},"source":{"system":"sec-edgar","filing":"0001578563-19-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856319000002/primary_doc.xml","form_type":"4"}},{"id":3803986,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-01T18:16:20.000Z","date":"2018-09-28","kind":"grant","acquired":true,"shares":2351,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2351,"derivative":{"exercise_price":4.67,"exercise_date":"2018-09-28","expiration_date":"2028-09-28","underlying":"Common Stock","underlying_shares":2351},"source":{"system":"sec-edgar","filing":"0001562180-18-004061","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218018004061/primarydocument.xml","form_type":"4"}},{"id":3878395,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-07-02T21:28:56.000Z","date":"2018-06-29","kind":"grant","acquired":true,"shares":2544,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2544,"derivative":{"exercise_price":4.34,"exercise_date":"2018-06-29","expiration_date":"2028-06-29","underlying":"Common Stock","underlying_shares":2544},"source":{"system":"sec-edgar","filing":"0001562180-18-003173","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218018003173/primarydocument.xml","form_type":"4"}},{"id":3927485,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T23:34:32.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":8357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in full on May 15, 2019, subject to the grantee's continued service on such vesting date."}],"balance_after":8357,"derivative":{"exercise_price":3.71,"exercise_date":"2019-05-15","expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":8357},"source":{"system":"sec-edgar","filing":"0001578563-18-000008","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856318000008/primary_doc.xml","form_type":"4"}},{"id":3969087,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-04-04T18:36:46.000Z","date":"2018-03-31","kind":"grant","acquired":true,"shares":2350,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2350,"derivative":{"exercise_price":4.29,"exercise_date":"2018-03-31","expiration_date":"2028-03-30","underlying":"Common Stock","underlying_shares":2350},"source":{"system":"sec-edgar","filing":"0001562180-18-001830","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218018001830/primarydocument.xml","form_type":"4"}},{"id":4106690,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-04T15:21:06.000Z","date":"2017-12-31","kind":"grant","acquired":true,"shares":3179,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3179,"derivative":{"exercise_price":3.2,"exercise_date":"2017-12-31","expiration_date":"2027-12-30","underlying":"Common Stock","underlying_shares":3179},"source":{"system":"sec-edgar","filing":"0001562180-18-000179","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218018000179/primarydocument.xml","form_type":"4"}},{"id":4191752,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-04T18:24:04.000Z","date":"2017-09-30","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10600,"derivative":{"exercise_price":0.85,"exercise_date":"2017-09-30","expiration_date":"2027-09-29","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001562180-17-003189","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218017003189/primarydocument.xml","form_type":"4"}},{"id":4248256,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-07-31T17:38:12.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":8357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date."}],"balance_after":8357,"derivative":{"exercise_price":0.57,"exercise_date":"2018-06-30","expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":8357},"source":{"system":"sec-edgar","filing":"0001562180-17-002533","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218017002533/primarydocument.xml","form_type":"4"}},{"id":4263332,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-07-05T17:40:22.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":14224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vested immediately and became exercisable in full upon grant on 6/30/2017."}],"balance_after":14224,"derivative":{"exercise_price":0.57,"exercise_date":"2017-06-30","expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":14224},"source":{"system":"sec-edgar","filing":"0001562180-17-002386","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218017002386/primarydocument.xml","form_type":"4"}},{"id":4359923,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-04-04T18:17:15.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":10131,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10131,"derivative":{"exercise_price":0.68,"exercise_date":"2017-03-31","expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":10131},"source":{"system":"sec-edgar","filing":"0001562180-17-001405","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218017001405/primarydocument.xml","form_type":"4"}},{"id":4503192,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-04T19:55:20.000Z","date":"2016-12-31","kind":"grant","acquired":true,"shares":3793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options immediately vested and became exercisable in full upon grant on December 31, 2016."}],"balance_after":3793,"derivative":{"exercise_price":0.88,"exercise_date":"2016-12-31","expiration_date":"2026-12-30","underlying":"Common Stock","underlying_shares":3793},"source":{"system":"sec-edgar","filing":"0001562180-17-000141","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156218017000141/primarydocument.xml","form_type":"4"}},{"id":4590281,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":128068,"kind":"person","name":"Gutry Phil","position":1,"cik":"0001653224","reported_name":"Gutry Phil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-03T19:11:39.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options immediately vested and became exercisable in full upon grant on September 30, 2016."}],"balance_after":886,"derivative":{"exercise_price":4.23,"expiration_date":"2026-09-29","underlying":"Common Stock","underlying_shares":886},"source":{"system":"sec-edgar","filing":"0001179110-16-030161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000117911016030161/edgar.xml","form_type":"4"}}]}